Oxytocin differentially modulates reward system responses to social and non-social incentives

What Was Tested

The paper reports a study of Oxytocin, published as a randomized controlled trial.

The researchers aimed to evaluate the effects of oxytocin administration on behavioral and neural responses to social and monetary incentives.

Time-series analysis was conducted to assess the influence of oxytocin on the hemodynamic response in the ventral tegmental area and substantia nigra (VTA/SN) and nucleus accumbens (NAc).

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.

Twenty-eight healthy adults (age 18-45 years) performed both monetary and social incentive tasks during blood oxygenation level dependent (BOLD) imaging.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Oxytocin.

Some participants received a placebo instead of Oxytocin, giving a reference point.

Each person switched between Oxytocin and the comparison at some point, usually with a gap in between.

Intranasal oxytocin or placebo was administered before each scan using a double blind, randomized, cross-over design.

Task performance and self-reported motivation and mood states were collected.

What Was Measured

The subject headings attached to it are Magnetic Resonance Imaging, Motivation, Nucleus Accumbens, Oxytocin, Reward, Social Behavior and Ventral Tegmental Area.

Author keywords: BOLD time-series, Psychopharmacology, Reward incentives, Social cognition and fMRI.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Psychopharmacology), a journal based in Germany.

More context: the Oxytocin compound page, all human trials.